- Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
- Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
- U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
- Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
- Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
- Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
- Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
- Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
- Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
More ▼
Key statistics
On Friday, Takeda Pharmaceutical Co Ltd (4502:TYO) closed at 4,129.00, 5.87% above its 52-week low of 3,900.00, set on Dec 18, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4,050.00 |
---|---|
High | 4,129.00 |
Low | 4,018.00 |
Bid | 4,122.00 |
Offer | 4,130.00 |
Previous close | 4,070.00 |
Average volume | 4.32m |
---|---|
Shares outstanding | 1.58bn |
Free float | 1.58bn |
P/E (TTM) | 36.57 |
Market cap | 6.53tn JPY |
EPS (TTM) | 112.79 JPY |
Annual div (ADY) | 188.00 JPY |
---|---|
Annual div yield (ADY) | 4.55% |
Div ex-date | Mar 28 2024 |
Div pay-date | Jun 27 2024 |
Data delayed at least 20 minutes, as of May 10 2024 07:00 BST.
More ▼